Murphy & Mullick Capital Management Corp Takes Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Murphy & Mullick Capital Management Corp bought a new position in Axon Enterprise, Inc. (NASDAQ:AXON) during the fourth quarter, Holdings Channel reports. The fund bought 2,553 shares of the biotechnology company’s stock, valued at approximately $1,517,000. Axon Enterprise comprises about 1.4% of Murphy & Mullick Capital Management Corp’s holdings, making the stock its 14th largest position.

A number of other institutional investors have also recently bought and sold shares of AXON. Public Sector Pension Investment Board raised its stake in Axon Enterprise by 19.2% during the 3rd quarter. Public Sector Pension Investment Board now owns 3,104 shares of the biotechnology company’s stock valued at $1,240,000 after purchasing an additional 500 shares during the period. Soros Capital Management LLC purchased a new position in shares of Axon Enterprise during the third quarter valued at $630,000. Friedenthal Financial raised its position in Axon Enterprise by 961.7% during the fourth quarter. Friedenthal Financial now owns 1,359 shares of the biotechnology company’s stock valued at $808,000 after buying an additional 1,231 shares during the period. Principal Financial Group Inc. boosted its position in Axon Enterprise by 33.1% during the 3rd quarter. Principal Financial Group Inc. now owns 136,302 shares of the biotechnology company’s stock worth $54,466,000 after acquiring an additional 33,869 shares during the period. Finally, XTX Topco Ltd boosted its position in Axon Enterprise by 20.6% during the 3rd quarter. XTX Topco Ltd now owns 5,650 shares of the biotechnology company’s stock worth $2,258,000 after acquiring an additional 964 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Insider Buying and Selling

In related news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total transaction of $271,831.50. Following the completion of the transaction, the director now owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. The trade was a 6.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeri Williams sold 307 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $552.72, for a total value of $169,685.04. Following the completion of the sale, the director now directly owns 1,627 shares of the company’s stock, valued at $899,275.44. This represents a 15.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $577.18 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The stock has a market capitalization of $44.23 billion, a P/E ratio of 149.14, a P/E/G ratio of 5.17 and a beta of 1.12. The business has a 50-day moving average of $591.92 and a two-hundred day moving average of $546.67. Axon Enterprise, Inc. has a fifty-two week low of $273.52 and a fifty-two week high of $715.99.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. JMP Securities reissued an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $500.00 to $700.00 in a research note on Tuesday, December 3rd. Needham & Company LLC reissued a “buy” rating and set a $600.00 target price on shares of Axon Enterprise in a research note on Wednesday, February 26th. Craig Hallum downgraded shares of Axon Enterprise from a “buy” rating to a “cautious” rating in a research note on Monday, March 10th. Finally, Northcoast Research cut Axon Enterprise from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average target price of $604.67.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.